The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer

Jones, Robin L.; Salter, Janine; A’Hern, Roger; Nerurkar, A; Parton, Marina; Reis‐Filho, Jorge S.; Smith, Ian; Dowsett, Mitchell

doi:10.1007/s10549-008-0081-7

Cited by 255 publications

(198 citation statements)

References 20 publications

Supporting

Mentioning

179

Contrasting

Unclassified

Order By: Relevance

“…Jones and colleagues also demonstrated that post-chemotherapy Ki67 level was a strong predictor of outcome for patients not achieving pCR [21]. Our present study demonstrated that expression of Ki67 in pre-treatment tumors was not associated with improved pCR rates, and that high Ki67 expression levels in post-treatment tumors were not correlated with poor prognosis in triple-negative breast cancer, although Ki67 expression levels were significantly decreased in post-treatment tumors compared with those in pretreatment samples.…”

Section: Discussionsupporting

confidence: 52%

Strong cytoplasmic expression of NF-κB/p65 correlates with a good prognosis in patients with triple-negative breast cancer

M¹,

Takahashi²,

Yamashiro³

et al. 2015

Surg Today

View full text Add to dashboard Cite

2 AbstractPurpose Recent studies have indicated that constitutive NF-κB activity could be involved in the proliferation of triple-negative breast cancer. were not associated with response to neoaduvant chemotherapy, although expression levels of cytoplasmic NF-κB/p65 intensity were significantly decreased in post-treatment tumor samples compared with those in pretreatment samples. All patients whose tumors showed strong cytoplasmic NF-κB/p65 expression before neoadjuvant chemotherapy are currently disease-free. Methods ConclusionOur results suggest that strong cytoplasmic NF-κB/p65 expression could be a prognostic marker in triple-negative breast cancer.

show abstract

Section: Discussionsupporting

confidence: 52%

Strong cytoplasmic expression of NF-κB/p65 correlates with a good prognosis in patients with triple-negative breast cancer

M¹,

Takahashi²,

Yamashiro³

et al. 2015

Surg Today

View full text Add to dashboard Cite

show abstract

“…Treatment was usually given to a total of 6 courses, and occasionally to eight in specific trials. Sixty-two of the patients selected were also included in another study assessing the prognostic value of pre-and post-neoadjuvant chemotherapy Ki67 [9].…”

Section: Clinical Methodologymentioning

confidence: 99%

Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer

Jones

Salter

A’Hern

et al. 2009

Breast Cancer Res Treat

Self Cite

108

View full text Add to dashboard Cite

Oestrogen receptor (ER) negative breast cancers are more likely to achieve a pathological complete response (pCR) to neoadjuvant chemotherapy compared to those with ER positive tumours. ER positive tumours exhibit low proliferation and ER negative cancers high proliferation. The aim of this study was to determine to what extent the better response of ER negative cancers correlates with proliferation rate. A retrospective analysis of a prospectively maintained database identified 175 neoadjuvant chemotherapy patients with tissue available for Ki67 analysis. On univariate analysis, pre-therapy Ki67 (P = 0.04), ER status (P = 0.002), HER2 status (P = 0.004) and grade (P = 0.0009) were associated with a pCR. In a multivariate model, HER2 was the only significant predictor of pCR. No significant relationship between pre-therapy Ki67 and relapse-free and overall survival was demonstrated. Ki67 is not an independent predictor of clinical CR or pCR. Aspects of ER status beyond its inverse relationship with proliferation may contribute to its predictive value for pCR.

show abstract

“…Recent studies have shown that the so called "Luminal A" subtype-characterized by low histological grade, low proliferation as measured by Ki67, high hormone receptor status, and negative HER2 status-was less responsive to chemotherapy, and that no preferable chemotherapy regimen could be defined for treatment of this subtype [2,10]. The potential usefulness of Ki67 in predicting response and long-term outcome has been explored by assessing preand post-treatment levels of Ki67 expression in neoadjuvant chemotherapy studies [11][12][13][14]. There is a general theory that biomarkers for rate of proliferation can predict responsiveness to systemic therapy, with highly proliferative tumors being more chemotherapy responsive.…”

Section: Introductionmentioning

confidence: 99%

“…Jones and colleagues also demonstrated that post-chemotherapy Ki67 level was a strong predictor of outcome for patients not achieving a pCR [12]. Patients would avoid an initial high-risk prognosis, even if they were node-positive or had a large tumor size, if they had a pCR.…”

mentioning

confidence: 99%

Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer

et al. 2013

View full text Add to dashboard Cite

show abstract

The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer

Cited by 255 publications

References 20 publications

Strong cytoplasmic expression of NF-κB/p65 correlates with a good prognosis in patients with triple-negative breast cancer

Strong cytoplasmic expression of NF-κB/p65 correlates with a good prognosis in patients with triple-negative breast cancer

Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer

Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer

Contact Info

Product

Resources

About